Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Central and peripheral α-synuclein in Parkinson disease detected by seed amplification assay.
Chahine LM, Beach TG, Adler CH, Hepker M, Kanthasamy A, Appel S, Pritzkow S, Pinho M, Mosovsky S, Serrano GE, Coffey C, Brumm MC, Oliveira LMA, Eberling J, Mollenhauer B; Systemic Synuclein Sampling Study. Chahine LM, et al. Among authors: coffey c. Ann Clin Transl Neurol. 2023 May;10(5):696-705. doi: 10.1002/acn3.51753. Epub 2023 Mar 27. Ann Clin Transl Neurol. 2023. PMID: 36972727 Free PMC article.
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort.
Simuni T, Merchant K, Brumm MC, Cho H, Caspell-Garcia C, Coffey CS, Chahine LM, Alcalay RN, Nudelman K, Foroud T, Mollenhauer B, Siderowf A, Tanner C, Iwaki H, Sherer T, Marek K; Parkinson’s Progression Marker Initiative Authors. Simuni T, et al. Among authors: coffey cs. NPJ Parkinsons Dis. 2022 Oct 22;8(1):140. doi: 10.1038/s41531-022-00404-w. NPJ Parkinsons Dis. 2022. PMID: 36273008 Free PMC article.
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts.
Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, Sherer T, Mollenhauer B, Siderowf A, Tanner C, Marek K; the Parkinson’s Progression Markers Initiative. Merchant KM, et al. Among authors: coffey c. NPJ Parkinsons Dis. 2023 Feb 28;9(1):30. doi: 10.1038/s41531-023-00468-2. NPJ Parkinsons Dis. 2023. PMID: 36854767 Free PMC article.
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.
Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kieburtz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Simuni T, Siderowf A, Singleton A, Seibyl J, Tanner CM; Parkinson's Progression Markers Initiative. Weintraub D, et al. Among authors: coffey cs. Mov Disord Clin Pract. 2023 Apr 25;10(6):943-955. doi: 10.1002/mdc3.13751. eCollection 2023 Jun. Mov Disord Clin Pract. 2023. PMID: 37332638 Free PMC article.
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kieburtz K, Marek K, Coffey CS; Parkinson’s Progression Markers Initiative. Brumm MC, et al. Among authors: coffey cs. J Parkinsons Dis. 2023;13(6):899-916. doi: 10.3233/JPD-223433. J Parkinsons Dis. 2023. PMID: 37458046 Free PMC article.
Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial.
Smith AG, Singleton JR, Aperghis A, Coffey CS, Creigh P, Cudkowicz M, Conwit R, Ecklund D, Fedler JK, Gudjonsdottir A, Hauer P, Herrmann DN, Kearney M, Kissel J, Klingner E, Quick A, Revere C, Stino A; NeuroNEXT NN108 TopCSPN Study Team. Smith AG, et al. Among authors: coffey cs. JAMA Neurol. 2023 Dec 1;80(12):1334-1343. doi: 10.1001/jamaneurol.2023.3711. JAMA Neurol. 2023. PMID: 37870862 Free PMC article. Clinical Trial.
Effects of AFQ056 on language learning in fragile X syndrome.
Berry-Kravis E, Abbeduto L, Hagerman R, Coffey CS, Cudkowicz M, Erickson CA, McDuffie A, Hessl D, Ethridge L, Tassone F, Kaufmann WE, Friedmann K, Bullard L, Hoffmann A, Veenstra-VanderWeele J, Staley K, Klements D, Moshinsky M, Harkey B, Long J, Fedler J, Klingner E, Ecklund D, Costigan M, Huff T, Pearson B; NeuroNEXT FXLEARN Investigators. Berry-Kravis E, et al. J Clin Invest. 2023 Aug 31;134(5):e171723. doi: 10.1172/JCI171723. J Clin Invest. 2023. PMID: 37651202 Free PMC article. Clinical Trial.
Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments.
Gibler RC, Peugh JL, Coffey CS, Chamberlin LA, Ecklund D, Klingner E, Yankey J, Korbee LL, Kabbouche M, Kacperski J, Porter LL, Reidy BL, Hershey AD, Powers SW. Gibler RC, et al. Among authors: coffey cs. Headache. 2023 Jun;63(6):805-812. doi: 10.1111/head.14474. Epub 2023 Feb 9. Headache. 2023. PMID: 36757131 Free PMC article. Clinical Trial.
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia.
Weintraub D, Nair AR, Kurth R, Brumm MC, York MK, Dobkin R, Marek K, Tanner C, Simuni T, Siderowf A, Galasko D, Chahine LM, Coffey C, Merchant K, Poston KL, Foroud T, Mollenhauer B, Brown EG, Kieburtz K, Frasier M, Sherer T, Chowdhury S, Alcalay RN, Videnovic A; Parkinson’s Progression Markers Initiative. Weintraub D, et al. Among authors: coffey c. medRxiv [Preprint]. 2024 Dec 13:2024.12.12.24318917. doi: 10.1101/2024.12.12.24318917. medRxiv. 2024. PMID: 39711699 Free PMC article. Preprint.
716 results